IFN-γ upregulates Survivin and ifi202 expression to induce survival and proliferation of tumor-specific T cells

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Zimmerman, Mary ^a   Yang, Dafeng ^a   Hu, Xiaolin ^a   Liu, Feiyan ^a   Singh, Nagendra ^a   Browning, Darren ^a   Ganapathy, Vadivel ^a   Chandler, Phillip ^a   Choubey, Divaker ^b   Abrams, Scott I ^c   Liu, Kebin ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CELL PROTEIN; GAMMA INTERFERON; PROTEIN IFI202; STAT1 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, MOUSE; CD3 ANTIGEN; GAMMA INTERFERON RECEPTOR; IFI202B PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; INTERFERON RECEPTOR; MONOCLONAL ANTIBODY; REPRESSOR PROTEIN; SIGNAL PEPTIDE; STAT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CYTOTOXIC T LYMPHOCYTE; DNA MICROARRAY; GEL MOBILITY SHIFT ASSAY; GENE SILENCING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSPLANTATION; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; IMMUNOTHERAPY, ADOPTIVE; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, INTERFERON; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 78649586932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014076     Document Type: Article

References (61)

1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, et al. (2001) IFN-c and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
2. Dunn GP, Old LJ, Schreiber RD (2004) The Three Es of Cancer Immunoediting. Annu Rev Immunol 22: 329-360.
3. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
4. Strater J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, et al. (2005) Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 54: 661-665.
5. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, et al. (2009) Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 69: 2685-2693.
6. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8: 299-308.
7. Leen AM, Rooney CM, Foster AE (2007) Improving T cell therapy for cancer. Annu Rev Immunol 25: 243-265.
8. Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, et al. (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169: 1961-1976.
9. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24: 175-208.
10. Schumacher TN, Restifo NP (2009) Adoptive T cell therapy of cancer. Curr Opin Immunol 21: 187-189.
11. June CH, Blazar BR, Riley JL (2009) Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9: 704-716.
12. Appay V, Douek DC, Price DA (2008) CD8+ T cell efficacy in vaccination and disease. Nat Med 14: 623-628.
13. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, et al. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99: 16168-16173.
14. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, et al. (2004) Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173: 7125-7130.
15. Rolle CE, Carrio R, Malek TR (2008) Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy. Cancer Res 68: 2984-2992.
16. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, et al. (2010) Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 33: 1-7.
17. Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ, Jr., et al. (2007) Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 30: 123-129.
18. Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, et al. (2008) Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol 181: 7400-7406.
19. Parish ST, Kim S, Sekhon RK, Wu JE, Kawakatsu Y, et al. (2847-2854).
20. Curtsinger JM, Mescher MF (2010) Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 22: 333-340.
21. Wesselborg S, Janssen O, Kabelitz D (1993) Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 150: 4338-4345.
22. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, et al. (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5: 677-685.
23. Ryan MH, Bristol JA, McDuffie E, Abrams SI (2001) Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope. J Immunol 167: 4286-4292.
24. + T cell receptors are consistent with an immunoglobulin- like structure for the receptor. J Exp Med 177: 119-125.
25. Yang D, Stewart TJ, Smith KK, Georgi D, Abrams SI, et al. (2008) Downregulation of IFN-cR in association with loss of Fas function is linked to tumor progression. Int J Cancer 122: 350-362.
26. Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI (2006) CTL Adoptive Immunotherapy Concurrently Mediates Tumor Regression and Tumor Escape. J Immunol 176: 3374-3382.
27. Yang D, Ud Din N, Browning DD, Abrams SI, Liu K (2007) Targeting lymphotoxin b receptor with tumor-specific T lymphocytes for tumor regression. Clin Cancer Res 13: 5202-5210.
28. Yang D, Thangaraju M, Greeneltch K, Browning DD, Schoenlein PV, et al. (2007) Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res 67: 3301-3309.
29. Choubey D, Lengyel P (1993) Interferon action: cytoplasmic and nuclear localization of the interferon-inducible 52-kD protein that is encoded by the Ifi 200 gene from the gene 200 cluster. J Interferon Res 13: 43-52.
30. McGough JM, Yang D, Huang S, Georgi D, Hewitt SM, et al. (2008) DNA methylation represses IFN-c-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells. Mol Cancer Res 6: 1841-1851.
31. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
32. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357.
33. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, et al. (2005) Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 175: 7046-7052.
34. Effros RB, Allsopp R, Chiu CP, Hausner MA, Hirji K, et al. (1996) Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 10: F17-F22.
35. Caldwell SA, Ryan MH, McDuffie E, Abrams SI (2003) The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol 171: 2402-2412.
36. Driessens G, Kline J, Gajewski TF (2009) Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 229: 126-144.
37. Mescher MF, Popescu FE, Gerner M, Hammerbeck CD, Curtsinger JM (2007) Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. Semin Cancer Biol 17: 299-308.
38. Deeths MJ, Kedl RM, Mescher MF (1999) CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol 163: 102-110.
39. Effros RB, Pawelec G (1997) Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? Immunol Today 18: 450-454.
40. Chen J, Panchanathan R, Choubey D (2008) Stimulation of T cells up-regulates expression of Ifi202, an interferon-inducible lupus susceptibility gene, through activation of JNK/c-Jun pathway. Immunol Lett 118: 13-20.
41. Xin H, D'Souza S, Jorgensen TN, Vaughan AT, Lengyel P, et al. (2006) Increased expression of Ifi202, an IFN-activatable gene, in B6.Nba2 lupus susceptible mice inhibits p53-mediated apoptosis. J Immunol 176: 5863-5870.
42. Choubey D, Panchanathan R (2008) Interferon-inducible Ifi200-family genes in systemic lupus erythematosus. Immunol Lett 119: 32-41.
43. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, et al. (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6: 975-990.
44. Kanno Y, Levi BZ, Tamura T, Ozato K (2005) Immune cell-specific amplification of interferon signaling by the IRF-4/8-PU.1 complex. J Interferon Cytokine Res 25: 770-779.
45. Xin H, Pramanik R, Choubey D (2003) Retinoblastoma (Rb) protein upregulates expression of the Ifi202 gene encoding an interferon-inducible negative regulator of cell growth. Oncogene 22: 4775-4785.
46. Veeranki S, Choubey D (2010) Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins. Immunol Lett 133: 1-5.
47. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438-441.
48. Koul D, Lapushin R, Xu HJ, Mills GB, Gutterman JU, et al. (1998) p202 prevents apoptosis in murine AKR-2B fibroblasts. Biochem Biophys Res Commun 247: 379-382.
49. D'Souza S, Xin H, Walter S, Choubey D (2001) The gene encoding p202, an interferon-inducible negative regulator of the p53 tumor suppressor, is a target of p53-mediated transcriptional repression. J Biol Chem 276: 298-305.
50. Kobayashi Y, Yukiue H, Sasaki H, Fukai I, Yokoyama T, et al. (2002) Developmentally regulated expression of survivin in the human thymus. Hum Immunol 63: 101-107.
51. Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS (2001) Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett 76: 169-173.
52. Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, et al. (2004) Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med 199: 399-410.
53. Song J, So T, Cheng M, Tang X, Croft M (2005) Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 22: 621-631.
54. Xing Z, Conway EM, Kang C, Winoto A (2004) Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 199: 69-80.
55. Zhao B, Song A, Haque R, Lei F, Weiler L, et al. (2009) Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression. J Immunol 182: 6744-6752.
56. Song J, Lei FT, Xiong X, Haque R (2008) Intracellular signals of T cell costimulation. Cell Mol Immunol 5: 239-247.
57. Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to interferon-c. Annu Rev Immunol 15: 749-795.
58. Winter H, Hu HM, McClain K, Urba WJ, Fox BA (2001) Immunotherapy of melanoma: a dichotomy in the requirement for IFN-c in vaccine-induced antitumor immunity versus adoptive immunotherapy. J Immunol 166: 7370-7380.
59. Fallarino F, Gajewski TF (1999) Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 163: 4109-4113.
60. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174: 4465-4469.
61. Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL (2003) CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J Immunol 171: 166-174.